Trust Company of Vermont’s Alnylam Pharmaceuticals ALNY Stock Holding History

Trust Company of Vermont’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$5.57K	Hold	14	–	–	﹤0.01%	922
2025 Q3	$6.38K	Hold	14	–	–	﹤0.01%	892
2025 Q2	$4.57K	Hold	14	–	–	﹤0.01%	935
2025 Q1	$3.78K	Hold	14	–	–	﹤0.01%	887
2024 Q4	$3.29K	Hold	14	–	–	﹤0.01%	907
2024 Q3	$3.85K	Buy	+14	New	+$3.65K	﹤0.01%	878
2022 Q4	–	Sell	-500	Closed	-$100K	–	873
2022 Q3	$100K	Buy	+500	New	+$95.4K	0.01%	384

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Trust Company of Vermont's ALNY Position: Q4 2025 in Review

Trust Company of Vermont held its Alnylam Pharmaceuticals (ALNY) position steady in Q4 2025 at 14 shares worth $5.57K. The position accounts for ﹤0.01% of the portfolio, ranked #922.

Trust Company of Vermont first reported a position in ALNY in Q3 2022 and has held it in 7 quarters since. The position peaked at $100K in Q3 2022. 849 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Trust Company of Vermont held 14 shares of Alnylam Pharmaceuticals worth $5.57K as of Q4 2025.
Trust Company of Vermont left its Alnylam Pharmaceuticals share count unchanged in Q4 2025.
Alnylam Pharmaceuticals made up ﹤0.01% of Trust Company of Vermont's portfolio in Q4 2025, its #922 holding.
Trust Company of Vermont first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
Trust Company of Vermont's Alnylam Pharmaceuticals position peaked at $100K in Q3 2022.
849 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Trust Company of Vermont's 13F filing for Q4 2025, filed 16 Jan 2026.